Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

--  Provides Update on Clinical and Other Developments

--  Initiates Financial Guidance for Full Year 2017

--  Management to Host Conference Call at 8:00 a.m. ET today

Malvern, PA – March 15, 2017 (GLOBE NEWSWIRE) –

“The year was a transformational year as we continued to make progress toward our goal of becoming a fully integrated biotechnology company.  In November 2016, we reported that two pivotal Phase 3 trials of our lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions.  In  February 2017, we submitted a New Drug Application (NDA) for A-101 40% Topical Solution for the treatment of SK to the U.S. Food and Drug Administration (FDA),” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.  “During 2016 we also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts.  Finally, we recently completed a Phase 1 clinical trial of ATI-50001, our investigational Janus Kinase (JAK) inhibitor, for the treatment of alopecia totalis and alopecia universalis.”

Clinical Pipeline Update